Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies

1 . A method for treating Crohn's disease in a subject in need of such a treatment, comprising administering to said subject a therapeutically effective amount of an antibody against interferon γ.

2 . The method according to claim 1 , wherein said treatment reduces severity of Crohn's disease.

3 . The method according to claim 1 , wherein said treatment reduces CDAI score of said subject.

4 . The method according to claim 3 , wherein said CDAI score is reduced by more than 70 points.

5 . The method according to claim 3 , wherein said CDAI score is reduced by more than 100 points.

6 . The method according to claim 3 , wherein said CDAI score is reduced by more than 125 points.

7 . The method according to claim 1 , wherein said treatment causes a remission of Crohn's disease indicated as CDAI score reduced to less than 150 points.

8 . The method according to claim 1 , wherein said antibody neutralizes interferon γ.

9 . The method according to claim 1 , wherein said antibody is a humanized antibody.

10 . The method according to claim 9 , wherein said humanized antibody is HuZAF.

11 . The method according to claim 1 , wherein said antibody binds to the same epitope as HuZAF.

12 . The method according to claim 1 , wherein said antibody is a chimeric antibody or fully human antibody.

13 . The method according to claim 1 , wherein said antibody has a binding affinity for human interferon γ of at least 10 8 M −1 .

14 . The method according to claim 13 , wherein said antibody has a binding affinity for human interferon γ of at least 10 9 M −1 .

15 . The method according to claim 1 , wherein the antibody is administered intravenously, intramuscularly, or subcutaneously.

16 . The method according to claim 1 , wherein the subject is a human.

17 . The method according to claim 1 , wherein said therapeutically effective amount is from 0.01 mg/kg to 100 mg/kg.

18 . The method according to claim 17 , wherein said therapeutically effective amount is from 0.1 mg/kg to 10 mg/kg.

19 . The method according to claim 1 , wherein said antibody is administered with a frequency from daily to every 6 month.

20 . The method according to claim 19 , wherein said antibody is administered daily, 2 or 3 times a week, biweekly, or monthly, every 6 weeks, or every 2 or 3 months.

21 . The method according to claim 1 , wherein said antibody is administered to said subject at least once.

22 . The method according to claim 16 , wherein said administering comprises administering of a first dose of said antibody and a second dose of said antibody.

23 . The method according to claim 22 , wherein said second dose is administered later than the first dose.

24 . The method according to claim 23 , wherein said second dose is less than said first dose.

25 . The method according to claim 24 , wherein said second dose is 50% of said first dose.

26 . The method according to claim 22 , wherein said first dose is 0.1, 1, 4, or 10 mg/kg.

27 . The method according to claim 22 , wherein said first dose is about 1.0 mg/kg and said second is about 0.1 mg/kg.

28 . The method according to claim 22 , wherein said first dose is about 1.0 mg/kg and said second dose is about 1.0 mg/kg.

29 . The method according to claim 22 , wherein said first dose is about 4.0 mg/kg and said second dose is about 0.1 mg/kg.

30 . The method according to claim 22 , wherein said first dose is about 4.0 mg/kg and said second dose is about 1.0 mg/kg.

31 . The method according to claim 22 , wherein said first dose is about 4.0 mg/kg and said second dose is about 4.0 mg/kg.

32 . The method according to claim 22 , wherein said first dose is about 10.0 mg/kg and said second dose is about 10.0 mg/kg.

33 . The method according to claim 23 , wherein said first dose is administered through intravenous infusion and said second dose is administered through subcutaneous injection.

34 . The method according to claim 23 , wherein the administering of said second dose repeats at least once.

35 . The method according to claim 34 , said antibody is administered daily, 2 or 3 times a week, biweekly, or monthly, every 6 weeks, or every 2 or 3 months.

36 . The method according to claim 35 , wherein said second dose is administered after 4 weeks.

37 . A method for treating psoriasis in a subject in need of such a treatment, comprising administering to said subject a therapeutically effective amount of an antibody against interferon γ.

38 . The method according to claim 37 , whereby said treatment reduces PSAI score of said subject.

39 . The method according to claim 38 , wherein the PSAI score is reduced by at least 50%.

40 . The method according to claim 39 , wherein the PSAI score is reduced by at least 75%.

41 . The method according to claim 37 , wherein at least 25% of patients receiving said treatment have a reduction of PSAI score by at least 50%.

42 . The method according to claim 37 , wherein the subject is a human.

43 . The method according to claim 37 , wherein said antibody neutralizes interferon Y.

44 . The method according to claim 37 , wherein said antibody is a humanized antibody.

45 . The method according to claim 44 , wherein said humanized antibody is HuZAF.

46 . The method according to claim 37 , wherein said antibody binds to the same epitope as HuZAF.

47 . The method according to claim 37 , wherein said antibody is a chimeric antibody or fully human antibody.

48 . The method according to claim 37 , wherein said antibody has a binding affinity for human interferon γ of at least 10 8 M −1 .

49 . The method according to claim 48 , wherein said antibody has a binding affinity for human interferon γ of at least 10 9 M −1 .

50 . The method according to claim 37 , wherein the antibody is administered intravenously, intramuscularly, or subcutaneously.

51 . The method according to claim 37 , wherein said therapeutically effective amount is from 0.01 mg/kg to 100 mg/kg.

52 . The method according to claim 51 , wherein said therapeutically effective amount is from 0.1 mg/kg to 10 mg/kg.

53 . The method according to claim 37 , wherein said antibody is administered with a frequency from daily to every 6 month.

54 . The method according to claim 53 , wherein said antibody is administered daily, 2 or 3 times a week, biweekly, or monthly, every 6 weeks, or every 2 or 3 months.

55 . The method according to claim 53 , wherein said antibody is administered to said subject at least once.